Enanta Pharmaceuticals, Inc. (ENTA)
NASDAQ: ENTA · Real-Time Price · USD
7.50
-0.01 (-0.13%)
At close: Jun 27, 2025, 4:00 PM
7.18
-0.32 (-4.27%)
After-hours: Jun 27, 2025, 7:42 PM EDT
Enanta Pharmaceuticals Employees
Enanta Pharmaceuticals had 131 employees as of September 30, 2024. The number of employees decreased by 14 or -9.66% compared to the previous year.
Employees
131
Change (1Y)
-14
Growth (1Y)
-9.66%
Revenue / Employee
$492,084
Profits / Employee
-$735,992
Market Cap
160.32M
Employees Chart
Related Stocks
Company Name | Employees |
---|---|
UnitedHealth Group | 400,000 |
Johnson & Johnson | 138,100 |
Abbott Laboratories | 114,000 |
AstraZeneca | 94,300 |
Novo Nordisk | 77,349 |
Novartis AG | 75,883 |
Merck & Co. | 75,000 |
AbbVie | 55,000 |
ENTA News
- 17 days ago - Enanta Pharmaceuticals' Partner AbbVie Receives U.S. FDA Approval of an Expanded Indication for MAVYRET® (glecaprevir/pibrentasvir) as the First and Only Treatment for People with Acute Hepatitis C Virus - Business Wire
- 4 weeks ago - Enanta Pharmaceuticals to Present at the Jefferies Global Healthcare Conference - Business Wire
- 5 weeks ago - Enanta Pharmaceuticals Announces Data from its Phase 2 Study of Zelicapavir in Children with Respiratory Syncytial Virus to be Presented at the 43rd Annual ESPID Meeting - Business Wire
- 6 weeks ago - Enanta Pharmaceuticals Reports Financial Results for its Fiscal Second Quarter Ended March 31, 2025 - Business Wire
- 2 months ago - Enanta Pharmaceuticals Announces Respiratory Syncytial Virus Data Presentation at ESCMID Global 2025 - Business Wire
- 3 months ago - Enanta Pharmaceuticals to Present at the H.C. Wainwright 3rd Annual Autoimmune & Inflammatory Disease Virtual Conference - Business Wire
- 3 months ago - Enanta Pharmaceuticals to Present Data for its Respiratory Syncytial Virus Program at the 13th International RSV Symposium - Business Wire
- 4 months ago - Enanta Pharmaceuticals Reports Financial Results for its Fiscal First Quarter Ended December 31, 2024 - Business Wire